Chris Freeman, an insider at Guardant Health Inc (GH), sold 25,987 shares of the company's stock on December 4, 2025. The shares were sold at a price of $106.71 each, resulting in a total transaction value of $2.77 million. Following this sale, Freeman retains 25,987 shares of Guardant Health.
Guardant Health is a precision oncology company headquartered in Palo Alto, California. The firm focuses on cancer treatment through proprietary blood-based tests and advanced analytics. It employs 1,999 full-time staff and went public on October 4, 2018. The company's offerings, such as the Guardant360 tests, provide critical insights for cancer care, from early detection to treatment selection for advanced cancer cases.
As of November 8, 2025, Guardant Health has a market capitalization of $12.1 billion and an earnings per share (EPS) of -3.21. Upcoming earnings reports are scheduled for April 28, 2026, and July 28, 2026, with estimated EPS of -0.66 and -0.61, respectively.
Insider transactions are reported to the SEC and can provide transparency regarding executive sentiment towards their company's stock. While Freeman's sale represents one data point, it is essential for investors to consider broader patterns of insider activity across multiple executives and time periods when assessing potential implications.